Drug profile · INN
ropeginterferon alfa-2b-njft
BESREMI
ropeginterferon alfa-2b-njft (BESREMI) is a interferon alpha/beta receptor positive modulator. Associated with Essential Pharma Limited. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — ropeginterferon alfa-2b-njft
- US status
- approved
- Class
- —
- Route
- SUBCUTANEOUS
- Patents
- 20
- Programs
- 0
- Data quality
- 0.89
Quick answer
ropeginterferon alfa-2b-njft (BESREMI) is a interferon alpha/beta receptor positive modulator. Associated with Essential Pharma Limited. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Interferon alpha/beta receptor positive modulator
Primary target: Interferon alpha/beta receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
Related & competitor drugs
Related patents
-
US 12109216
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 11786536
Salts of potassium ATP channel openers and uses thereof
granted -
US 11786524
Pharmaceutical compounds
granted -
US 11690933
Absorbent aliphatic polyurethane foam product
granted -
US 11445997
Ultrasound imaging of biomarker sensitive hydrogels
granted -
US 11273191
Administering compositions for improved immune system functioning
granted -
US 11045478
Salts of potassium ATP channel openers and uses thereof
granted -
US 10973817
Pharmaceutical compounds
granted -
US 10874676
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 10702590
Compositions and methods for treating thyroid disease
granted -
US 10456408
Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
granted -
US 10105289
Biomimetic mineral based endodontic cement composition and uses thereof
granted -
US 10098379
Device and method for simulating chemosensation of smoking
granted -
US 10085998
Salts of potassium ATP channel openers and uses thereof
granted -
US 10058557
Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome
granted -
US 9765043
Salts of potassium ATP channel openers and uses thereof
granted -
US 9381202
Salts of potassium ATP channel openers and uses thereof
granted -
US 9211277
Dietary supplement composition
granted -
US 8765933
Asynthesis of β-nucleosides
granted -
US 8716287
Pharmaceutical compounds
granted
Frequently asked questions
What is ropeginterferon alfa-2b-njft?
ropeginterferon alfa-2b-njft (BESREMI) is a interferon alpha/beta receptor positive modulator. Associated with Essential Pharma Limited. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for ropeginterferon alfa-2b-njft?
BESREMI is a marketed brand name for ropeginterferon alfa-2b-njft. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ropeginterferon alfa-2b-njft?
ropeginterferon alfa-2b-njft has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.